Drug intelligence / Profile preview

EcoActive (Intralytix, Inc.)

Development stage: Unknown
Lead developer: Intralytix
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**EcoActive** is an investigational, orally administered fixed bacteriophage cocktail developed by Intralytix for inactive Crohn's disease. The product contains bacteriophages selected to infect and lyse intestinal adherent-invasive *Escherichia coli*, a bacterial pathobiont associated with Crohn's disease. EcoActive is being evaluated in the randomized Phase 1/2a study NCT03808103 for safety, effects on stool AIEC levels, and clinical activity. ([intralytix.com](https://www.intralytix.com/article/114))

Brand names: EcoActive

Beyond the preview

Go deeper on EcoActive (Intralytix, Inc.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EcoActive (Intralytix, Inc.).

Explore the full profile